RS50389B - Use of antiprogestins for prophylaxis and treatment of hormone dependent diseases - Google Patents

Use of antiprogestins for prophylaxis and treatment of hormone dependent diseases

Info

Publication number
RS50389B
RS50389B YUP-301/03A YUP30103A RS50389B RS 50389 B RS50389 B RS 50389B YU P30103 A YUP30103 A YU P30103A RS 50389 B RS50389 B RS 50389B
Authority
RS
Serbia
Prior art keywords
treatment
antiprogestins
prophylaxis
cancer
dependent diseases
Prior art date
Application number
YUP-301/03A
Other languages
Serbian (sr)
Inventor
Rosemarie Lichtner
Jens Hoffmann
Gerhard Siemeister
Martin Schneider
Ulrike Fuhrmann
Original Assignee
Bayer Schering Pharma Aktiengesellschaft,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft, filed Critical Bayer Schering Pharma Aktiengesellschaft,
Publication of YU30103A publication Critical patent/YU30103A/en
Publication of RS50389B publication Critical patent/RS50389B/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Upotreba antiprogestina 11ß-(4-acetilfenil)-17 ß -hidroksi-17 ß -(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona ili njegovog farmaceutski prihvatljivog derivata ili analoga za dobijanje medikamenta za lečenje tipa kancera odabranog od grupe koja sadrži kancerdojke, kancer jajnika, kancer endometrijuma, mijelom, anovulatornog infertiliteta i/ili meningioma kod sisara. Prijava sadrži 6 zavisnih zahteva.Use of antiprogestin 11ß- (4-acetylphenyl) -17 ß-hydroxy-17 ß - (1,1,2,2,2-pentafluoroethyl) -estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof for the preparation of a medicament for the treatment of a type of cancer selected from the group consisting of cancer, ovarian cancer, endometrial cancer, myeloma, anovulatory infertility and / or meningioma in mammals. The application contains 6 dependent requests.

YUP-301/03A 2000-10-18 2001-10-17 Use of antiprogestins for prophylaxis and treatment of hormone dependent diseases RS50389B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24098800P 2000-10-18 2000-10-18
EP00250341 2000-10-18

Publications (2)

Publication Number Publication Date
YU30103A YU30103A (en) 2006-08-17
RS50389B true RS50389B (en) 2009-12-31

Family

ID=34072454

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-301/03A RS50389B (en) 2000-10-18 2001-10-17 Use of antiprogestins for prophylaxis and treatment of hormone dependent diseases

Country Status (8)

Country Link
AR (1) AR032371A1 (en)
EA (1) EA007529B1 (en)
EC (1) ECSP034605A (en)
PE (1) PE20020520A1 (en)
RS (1) RS50389B (en)
UA (1) UA75615C2 (en)
UY (1) UY26965A1 (en)
ZA (1) ZA200303793B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (en) * 1997-02-07 1998-08-13 Schering Ag Anti-gestagen effective steroids with fluorinated 17alpha alkyl chain

Also Published As

Publication number Publication date
UY26965A1 (en) 2002-06-20
EA200300480A1 (en) 2003-10-30
ECSP034605A (en) 2003-06-25
AR032371A1 (en) 2003-11-05
UA75615C2 (en) 2006-05-15
EA007529B1 (en) 2006-10-27
ZA200303793B (en) 2004-08-16
YU30103A (en) 2006-08-17
PE20020520A1 (en) 2002-06-15

Similar Documents

Publication Publication Date Title
CY1104981T1 (en) USE OF ANTI-PROGESTONES FOR THE PREVENTION AND TREATMENT OF HORMONE DEPENDENT DISEASES
KR970704451A (en) Progesterone Antagonists Useful for Preparing Medicaments for Treating Dysfunctional Uterine Bleeding
BR0209468A (en) Pharmaceutically acceptable compound or salts or solvates thereof, pharmaceutical composition, use of a compound, and method of treating an HPP-mediated disease or condition
DK0402950T3 (en) Treatment of postmenopausal disadvantages
NZ535616A (en) Indolymaleimide derivatives as protein kinase c inhibitors
ES2124905T3 (en) ANTIGLUCOCORTICOID STEROIDS INTENDED FOR THE TREATMENT OF ANXIETY DISORDERS.
GR910100067A (en) Aromatase inhibitors
NO20056153L (en) Preparation comprising antiprogestins and pure antiostrogens for prophylaxis and treatment of hormone-dependent diseases
HK1087357A1 (en) Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1- propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder.
RS50389B (en) Use of antiprogestins for prophylaxis and treatment of hormone dependent diseases
RS50350B (en) Use of 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one for the preparation of medicament for the treatment fo breast, ovarian, endometrial kancer, myeloma and meningioma
KR890009407A (en) Pharmaceutical dosage unit for the treatment of menopause and osteoporosis
SI1326617T1 (en) Use of 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-one for the preparation of a medicament for the treatment fo breast, ovarian, endometrial cancer, myeloma and meningioma
RS50396B (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
TW200733955A (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases